Moreover, the plasma levels of ANXA1 in patients with T2D correlated positively with fatty liver index, a surrogate marker of hepatic lipid accumulation (Figure 1B), and serum LDL-C and total cholesterol (Figures 1C,D), thus implying a relation between elevated circulating ANXA1 levels and a complex metabolic pattern, including altered glucose control, hepatic steatosis and dyslipidemia. The gene discussed is ANXA1; the disease is Hepatic steatosis.